Frantic demand for drugs to treat obesity from Novo Nordisk, Eli Lilly, and others could support a global market worth an eye-watering $60 billion within the next decade, according to a Morningstar analyst.Morningstar’s equity strategist Karen Anderson has predicted that by 2032 Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide) – along with a follow-up combination in […]
